A new study shows an improvement in sexual function in depressed patients who did not respond to conventional treatment with lumateprone

A new study, conducted by researchers from the University of Virginia School of Medicine, showed that patients with major depressive disorder (MDD) who did not respond adequately to traditional antidepressants experienced a significant improvement in sexual function when they received the drug “lumateprone” as additional treatment.

In their study, which included 480 patients, significant improvements in sexual function were observed in patients who were randomly selected to receive a daily dose of 42 mg of lumateprone in addition to their antidepressant treatment, compared to patients who received a placebo as an additional treatment. These improvements were seen in a variety of patient groups, including those who had experienced sexual dysfunction before the study began, women, and adults of all ages.

According to the study published in The Journal of Clinical Psychiatry, the experiences included multiple aspects of sexual function, such as sexual desire, arousal, orgasm, and pleasure. Approximately 68 percent of patients with major depressive disorder suffer from sexual dysfunction, and sexual side effects of antidepressants are a major reason why patients stop treatment.

In a statement on Tuesday, lead researcher Dr. Anita H. Clayton, a psychiatrist at the University of Virginia School of Medicine, praised these findings as an important step forward. Major depressive disorder affects approximately 21 million American adults, according to the Anxiety and Depression Association of America. Researchers explain that sexual dysfunction increases the risk of major depressive disorder, while this disorder and its treatments are also common causes of the disorder.

“If an individual taking antidepressants does not see a significant reduction in symptoms, they face a higher combined risk of developing sexual dysfunction,” Clayton said. The researchers sought to find out whether lumateprone - an antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia and depression associated with bipolar disorder, as well as an add-on treatment to antidepressants in cases of major depressive disorder - could improve sexual function in patients with major depression who were already receiving treatment with traditional antidepressants but had not achieved a reduction in depressive symptoms of more than 50 percent.

The researchers found that participants who received additional treatment with lumateprone experienced significant improvements in depressive symptoms - according to the Montgomery-Asberg Depression Rating Scale (MADRS) - and in sexual function - according to the Changes in Sexual Function Questionnaire (CSFQ-14) - by the end of the 43-day treatment period.

According to the results of the study, examinations showed that 82.5 percent of the participants were suffering from sexual dysfunction at the beginning of the experiments, and at the end of the study, more than a quarter of the participants reported that they had regular sexual function. It appears that women benefited more than men, but researchers point out that more research is needed to verify this. Both genders reported improvements in sexual pleasure and arousal.

In addition, study participants who did not have sexual dysfunction and received lumateprone did not report any deterioration in their sexual function during the trial period. Clayton said: “Depressive symptoms and sexual function improved in patients who were randomly selected to receive lumateprone.” This improvement was particularly noticeable among women, although both sexes saw an improvement in levels of pleasure, desire, and sexual interest.”